Read by QxMD icon Read

Therapeutic Delivery

Micaela Ponce-Ponte, Carolina Aloisio, Diana Marcela Romero-Guerra, Sandra Gracia-Vásquez, Claudia Garnero, Marcela Longhi
AIM: Binary and ternary complexes with hydroxypropyl-β-cyclodextrin (HPβCD), using glutamic acid (GA), proline or lysine as the third component, were developed to increase the solubility and the dissolution rate of norfloxacin (NOR). METHODS/RESULTS: Complexation was evaluated by phase solubility studies, obtaining the highest NOR solubility with GA and HPβCD. Thermal analysis suggested that different kinds of interactions occur among NOR, HPβCD and each amino acid, and when the systems were prepared by kneading or by means of freeze-drying technique...
September 2018: Therapeutic Delivery
Iain Simpson
No abstract text is available yet for this article.
September 2018: Therapeutic Delivery
Sandeep Urandur, Disha Marwaha, Shalini Gautam, Venkatesh T Banala, Madhu Sharma, Prabhat R Mishra
The aim of this article is to collate the recent developments in the field of drug delivery, medical therapeutics and diagnostics specifically involving the nonlamellar liquid crystalline (NLC) systems. This review highlights different NLC phases having cubic, hexagonal and sponge internal structures, and their application in the field of drug delivery, such as dose reduction, toxicity reduction and therapeutic efficacy enhancement either in the form of nanoparticles, colloidal dispersion or gels. In addition, application of NLC systems as vehicles for peptides, proteins and as a theranostic system in cancer and other disease conditions is also elaborated, which is a growing platform of interest...
September 2018: Therapeutic Delivery
Analía Simonazzi, Alicia Graciela Cid, Alejandro Javier Paredes, Laureano Schofs, Elio Emilio Gonzo, Santiago Daniel Palma, José María Bermúdez
AIM: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole (ABZ) solubility and dissolution profiles. METHODS: ABZ/poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical ABZ and a commercial formulation. RESULTS: Poloxamer 407 increased exponentially ABZ solubility, in about 400% when 95% w/w of polymer compared with its absence...
September 2018: Therapeutic Delivery
Rodrigo Cristofoletti, Stephan Schmidt, Andrea Diniz
No abstract text is available yet for this article.
September 2018: Therapeutic Delivery
Elsie E Gaskell, Tina Ha, Ashley R Hamilton
AIM: The chemical composition of layered double hydroxides (LDHs) affects their structure and properties. The method of ibuprofen (IBU) intercalation into LDHs may modify its release, reduce adverse effects and decrease the required dosing frequency. METHODOLOGY: This study investigates the effects of four different LDHs; MgAl-LDH, MgFe-LDH, NiAl-LDH and NiFe-LDH on in vitro release of IBU intercalated by coprecipitation and anionic-exchange. RESULTS: MgAl-LDH was the most crystalline and substitution of either cation decreased LDH order...
September 2018: Therapeutic Delivery
Elaine Harris
The present Industry Update covers the period 1-31 May 2018. Sources of information included company press releases, regulatory and patent agency notices and various news websites. Regulatory approvals of this month include Novartis (Basel, Switzerland) and Amgen's (CA, USA), Aimovig as a preventive treatment for migraines and Breckenridge's (CO, USA) delayed-release capsules, Duloxetine. This month also saw DURECT (CA, USA) and Sandoz (Upper Bavaria, Germany) renegotiate their agreement for the development, manufacture and commercialization of the extended-release depot product POSIMIR® ...
September 2018: Therapeutic Delivery
Maira N Pereira, Camila Y Ushirobira, Marcilio Ss Cunha-Filho, Guilherme M Gelfuso, Tais Gratieri
Alopecia is the partial or total reduction of hair in a specific area of the skin that affects millions of men and women worldwide. Most common approved treatments present inconvenient therapeutic regimes and serious adverse effects. In this scenario, nanoencapsulation has emerged as a relatively simple technology for improving the therapeutic outcome of this pathology, promoting a targeted drug delivery with enhanced local bioavailability, which could reduce the adverse effects. Herein, we present some recent studies involving the nanosystems developed for the pharmacological treatment of alopecia, highlighting how each system represents an improvement in relation to conventional drug products and the future perspectives of these new technologies in reaching the market...
August 2018: Therapeutic Delivery
Puja S Gaikwad, Rinti Banerjee
Gliomas are the most common malignancies of the brain and have a mean survival of 12 months with only 5-10% of the patients surviving for more than 5 years, independent of treatment after diagnosis. Conventional treatment modalities have found the modest success in reducing tumor burden and metastases. Presence of different biological barriers and drug-resistance efflux transporters are crucial for tumor recurrence and treatment failure. Nanotechnology may amend these circumstances by targeting residual infiltrating malignant cells with minimal damage to normal cells, on-demand release and an improved cellular uptake by tumor cells...
August 2018: Therapeutic Delivery
Mozhdeh Mirahadi, Saeed Ghanbarzadeh, Marjan Ghorbani, Amin Gholizadeh, Hamed Hamishehkar
Molecular and diagnostic imaging has been recently a subject of intense research in the treatment of numerous diseases. In medical imaging, there are different modalities with unique strengths including MRI, ultrasound imaging, computed tomography, positron emission tomography and single photon emission computed tomography. These systems need specific contrast agents to achieve a suitable image with the best quality. Nanoparticles represent an innovative tool in imaging field research and diagnostics of various diseases, especially cancerous ones...
August 2018: Therapeutic Delivery
Maged S Habib
Diabetic macular edema (DME) is one of the major causes of blindness, caused primarily by hyperglycemia and results from multiple pathological processes mostly secondary to increased levels of VEGF and other inflammatory cytokines. DME management includes control of systemic risk factors together with laser photocoagulation, frequent intraocular injections of anti-VEGF agents and steroids implants. Recent adoption of novel alternative drug delivery options has led to the development of sustained release ocular implants with longer duration of action with less injection frequency...
August 2018: Therapeutic Delivery
Lauren D Field, Okhil K Nag, Ajmeeta Sangtani, Kelly E Burns, James B Delehanty
The systemic delivery of drugs to the body via circulation after oral administration is a preferred method of drug administration during cancer treatment given its ease of implementation. However, the physicochemical properties of many current anticancer drugs limit their effectiveness when delivered by systemic routes. The use of nanoparticles (NPs) has emerged as an effective means of overcoming the inherent limitations of systemic drug delivery. We provide herein an overview of various NP formulations that facilitate improvements in the efficacy of various anticancer drugs compared with the free drug...
July 2018: Therapeutic Delivery
Daniel S Quintana, Knut T Smerud, Ole A Andreassen, Per G Djupesland
The neuropeptide oxytocin plays an evolutionarily conserved role in mammalian social behavior. Despite striking effects on animal social behavior after intracerebroventricular drug delivery, this delivery mode is impractical in humans. Intranasal oxytocin delivery provides a noninvasive alternative to increase central oxytocin activity, and has shown promise as a treatment for psychiatric illnesses. Intranasal oxytocin delivery is purported to increase central oxytocin concentrations via channels surrounding trigeminal and olfactory nerve fibers, which may facilitate increased activity at central oxytocin receptors...
July 2018: Therapeutic Delivery
Elaine Harris
The present industry update covers the period 1-31 March 2018. Sources of information included company press releases, regulatory and patent agencies notices and various news websites. A number of companies reported positive early-stage clinical trial results for therapeutic candidates enabled by different delivery strategies including Cerenis Therapeutics Inc. and Enteris. March also saw the announcement of some significant collaborations; Bluebird Bio and Celgene announced plans for a collaboration with a view to developing a novel CAR-T therapy, and Windtree Therapeutics Inc...
July 2018: Therapeutic Delivery
Himanshu Kathuria, Jaspreet S Kochhar, Lifeng Kang
Delivering therapeutics in a painless manner is one of the many objectives for the treatment of clinical conditions. Micro and nanoneedles are small-scale devices that can help overcome the resistance encountered during drug diffusion by creating conduits of small dimensions through biomembranes. Microneedles for drug delivery applications were manually produced until the 1990s and after this the high precision technology from the semiconductor industry was adopted for their production [ 1 ]. Over  the  last decade or so, microneedles for transdermal applications have been widely studied...
July 2018: Therapeutic Delivery
Peter Timmins
No abstract text is available yet for this article.
July 2018: Therapeutic Delivery
James Hamilton
J Hamilton currently serves as vice president of Clinical Development at Arrowhead Pharmaceuticals, Inc. (CA, USA), where he is responsible for clinical strategy, clinical trial design, implementation and execution. In this role, he managed the ARC-520, ARC-521 and ARC-AAT global programs. Previously, he was medical director and head of Corporate Development at Arrowhead. He led Arrowhead's acquisition of the Novartis RNAi assets and led Arrowhead's $670 million cardiovascular deal with Amgen (CA, USA). He earned an MD and MBA at The Ohio State University (USA) and is a licensed physician with board certification in emergency medicine...
July 2018: Therapeutic Delivery
Simseok A Yuk, Diego A Sanchez-Rodriguez, Michael D Tsifansky, Yoon Yeo
Sepsis and septic shock are life-threating conditions, which form a continuum of the body's response to overwhelming infection. The current treatment consists of fluid and metabolic resuscitation, hemodynamic and end-organ support, and timely initiation of antibiotics. However, these measures may be ineffective and the sepsis-related mortality toll remains substantial; therefore, an urgent need exists for new therapies. Recently, several nanoparticle (NP) systems have shown excellent protective effects against sepsis in preclinical models, suggesting a potential utility in the management of sepsis and septic shock...
May 1, 2018: Therapeutic Delivery
Khaled Greish
Khaled Greish speaks to Hannah Makin, Commissioning Editor: Khaled Greish is Associate Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Center, Arabian Gulf University, Kingdom of Bahrain. His previous appointments included Senior lecturer of Pharmacology at the University of Otago, New Zealand, and Assistant Professor of Pharmaceutical Chemistry at University of Utah (UT, USA). He has published >70 peer reviewed papers, and ten book chapters in the field of targeted anticancer drug delivery...
May 1, 2018: Therapeutic Delivery
F Philipp Seib
Silk is an important biopolymer for (bio)medical applications because of its unique and highly versatile structure and its robust clinical track record in human medicine. Silk can be processed into many material formats, including physically and chemically cross-linked hydrogels that have almost limitless applications ranging from tissue engineering to biomedical imaging and sensing. This concise review provides a detailed background of silk hydrogels, including silk structure-function relationships, biocompatibility and biodegradation, and it explores recent developments in silk hydrogel utilization, with specific reference to drug and cell delivery...
May 1, 2018: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"